[1] 中华医学会肝病学分会. 肝硬化诊治指南. 中华肝脏病杂志, 2019,27(11)?: 846-865.
[2] De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[3] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol, 2022, 77(6): 1564-1572
[4] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER) an open-label randomised trial. Lancet, 2018,391(10138):2417-2429.
[5] Caraceni P, Tufoni M, Zaccherini G, et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol, 2021, 74(2): 340-349.
[6] China L, Freemantle N, Forrest E, et al. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. N Engl J Med, 2021, 384(9): 808-817.
[7] Zaccherini G, Baldassarre M, Tufoni M, et al. Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database. Am J Gastroenterol, 2023, 118(1): 168-173
[8] Xu T, Liu W, Huang R. Can albumin reduce the mortality of patients with cirrhosis and ascites? A meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol, 2023, 35(1): 80-88.
[9] Villanueva C, Albillos A, Genesca J, et al. beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2019, 393(10181): 1597-1608.
[10] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J. Hepatol. 2022, 77, 807-824
[11] Yu X, Jin Y, Zhou W, et al. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Front Cell Infect Microbiol, 2021, 11: 761192.
[12] Tan W, Wang J, Shi PM, et al. Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy. J Clin Transl Hepatol, 2022, 10(6): 1099-106.
[13] Deleuran T, Watson H, Vilstrup H, et al. Spontaneous bacterial peritonitis has no effect on the long-term prognosis of cirrhosis patients with ascites. Ann Hepatol, 2022, 27(4): 100711.
[14] Huang CH, Wang SF, Lee CH, et al. Bacteremia (Sepsis), Hepatorenal Syndrome, and Serum Creatinine Levels Rather than Types or Microbial Patterns Predicted the Short-Term Survival of Cirrhotic Patients Complicated with Spontaneous Bacterial Peritonitis. Diagnostics (Basel), 2022, 13(1):94.
[15] Biggins SW, Angeli P, Garcia-Tsao G,et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74:1014-1048
[16] Praharaj DL, Premkumar M, Roy A, et al. Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial. J Clin Exp Hepatol, 2022, 12(2): 336-342.
[17] Huang L, Yu Q, Peng H, et al. Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis. Medicine (Baltimore), 2022, 101(51): e32335.
[18] Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med, 2021, 384(9): 818-828.
[19] Curry MP, Vargas HE, Befeler AS, et al. Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies. Hepatol Commun, 2023, 7(1): e1307
[20] Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation, 2016, 100(7): 1440-1452.
[21] Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J, 2023,61(1):2200879.
[22] Carey EJ, Lai JC, Wang C , et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl, 2017, 23(5): 625-633.
[23] Di Cola S, Nardelli S, Ridola L, et al. Ammonia and the Muscle: An Emerging Point of View on Hepatic Encephalopathy. J Clin Med, 2022, 11(3): 611.
[24] Kumar VV, Kothakota SR, Nair AK, Et al. Impact of sarcopenia on post-liver transplant morbidity and mortality in cirrhotic patients. Indian J Gastroenterol, 2022, 41(5): 440-445.
[25] Gioia S, Nardelli S, Faccioli J, Ridola L. Post TIPS hepatic encephalopathy: Look at muscle and fat! Clin Nutr. 2022 May;41(5):1150.
[26] Liu J, Ma J, Yang C, et al. Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement. Radiology, 2022, 303(3): 711-719.
[27] Huang S, Liu J, Cai J, Zhou C, Wang Y, Yang C, Li T, Chen Y, Ju S, Wang C, Yao W, Bai Y, Xiong B. Predictors of Improvement of Sarcopenia after TIPS Creation in Cirrhotic Patients. J Vasc Interv Radiol. 2022 Dec 28: S1051-0443(22)01901-7. |
